Quest Diagnostics Incorporated DGX

Full chart Compare
Set alert

Price alert · DGX

All alert types
252.89 USD -2.79 (-1.09%)

Nov 5, 2026, 2:22 PM EST

252.27 Day range 259.00
173.49 52-week range 255.68
YTD
+45.73%
1 year
+41.87%
Market cap
27.95B
Revenue (ttm)
11.84B
Profit margin
9.54%
EPS (ttm)
10.04
Shares out
110.37M
P/E ratio
25.22
Forward P/E
21.34
Dividend
3.44 (1.37%)
Ex-dividend date
Oct 5, 2026
YTD return
+45.73%
1-year return
+41.87%
Volume
364.09K
Avg volume
1.00M
Open
258.74
Previous close
255.68
Day's range
252.27 – 259.00
52-week range
173.49 – 255.68
Beta
0.55
Analysts
Buy
Price target
257.27 (+1.7%)
Earnings date
Feb 9, 2027

YTD +78.56 (+45.20%)

175200225250Feb 3Apr 7Jun 5Aug 6Oct 7252.35

Key statistics

Enterprise value
33.18B
PEG ratio
1.61
Price / sales
2.38
Price / book
3.68
Dividend yield
1.39%
Payout ratio
25.10%
Revenue growth
10.00%
Free cash flow
872.50M
Total cash
797.00M
Total debt
6.40B
Return on equity
15.32%
Short % of float
3.25%
50-day average
238.73
200-day average
212.74

Financials — quick view

All financials
DGX Revenue — quarterly 3.10B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
DGX Net income — quarterly 312.00M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
DGX EPS — quarterly 2.82
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

DGX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 9, 2027Dec 30, 20262.68———
Oct 22, 2026Sep 30, 20262.873.00+0.13+4.53%
Jul 23, 2026Jun 30, 20262.823.12+0.30+10.64%
Apr 21, 2026Mar 31, 20262.372.50+0.13+5.49%
Feb 10, 2026Dec 31, 20252.362.42+0.06+2.54%
Oct 21, 2025Sep 30, 20252.502.60+0.10+4.00%

Upgrades / downgrades

DGX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 7, 2026BarclaysmainOverweightOverweight
Sep 21, 2026Truist SecuritiesmainHoldHold
Sep 8, 2026UBSmainNeutralNeutral
Jul 28, 2026JP MorganmainNeutralNeutral
Jul 24, 2026UBSmainNeutralNeutral
Jul 24, 2026MizuhomainOutperformOutperform

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States

News

Your note

Sign in to keep a note on DGX — it syncs with the Stock Master app.

Insider holders

DGX insider holders
InsiderRelationLatest transactionDateShares held
DAVIS J E CAUSEYChief Executive OfficerStock Award(Grant)Mar 3, 2026142,423
DAVIS JAMES EChief Executive OfficerSaleAug 31, 2026122,423
DEPPE MICHAEL JOfficerStock Award(Grant)Mar 3, 202635,196
DOHERTY CATHERINE TOfficerSaleMar 4, 202671,624
GREGG VICKY BDirectorStock Award(Grant)Jul 21, 202618,386
MAIN TIMOTHY LDirectorPurchaseJul 21, 202627,460

Institution ownership

DGX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.43%9,275,4112.37BJun 29, 2026
Vanguard Capital Management LLC6.57%7,233,3941.85BJun 29, 2026
Vanguard Portfolio Management LLC5.57%6,131,0451.57BJun 29, 2026
State Street Corporation5.01%5,516,6431.41BJun 29, 2026
Price (T.Rowe) Associates Inc4.95%5,444,9861.39BJun 29, 2026
Boston Partners4.31%4,744,4731.21BJun 29, 2026

Fund ownership

DGX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.19%3,514,526898.28MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.61%2,868,317733.11MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund2.18%2,398,588613.06MJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.34%1,470,712375.90MSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%1,434,404366.62MSep 29, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.25%1,373,267350.99MSep 29, 2026